Active Biotech Interim Report January-March 2004

SAIK-MS project advancing further

TTS CD3 for lung cancer progressing according to plan

New collaboration with Avidex Ltd.

Phase I study for the SLE project planned to start during third quarter

Patient study for prostate-cancer project TASQ to commence during the autumn of 2004

Focus on clinical projects being implemented, negotiations in accordance with labour market legislation completed

Loss after net financial items SEK 42.5 M (loss: 60.4)

Loss per share for the period amounted to SEK 1.26 (loss: 4.72)

Loss after tax SEK 42.5 M (loss: 60.4)

Active Biotech Interim Report January-March 2004

Pièces jointes